Embolieprophylaxe bei Vorhofflimmern

Zusammenfassung

Die Thromboembolieprophylaxe bei Vorhofflimmern/-flattern ist ein zentrales therapeutisches Element. Neben den neuen oralen Antikoagulanzien hat sich der Vorhofohroccluder als Alternative insbesondere bei hohem Blutungsrisiko etabliert.

Abstract

Thrombo-embolic prophylaxis is a key element within the therapy of atrial fibrillation/atrial flutter. Besides new oral anticoagulants the concept of left atrial appendage occlusion has approved to be a good alternative option, especially in patients with increased risk of bleeding.

Schlüsselwörter

Thromboembolieprophylaxe - Vorhofflimmern - Vorhofohroccluder

Keywords

thrombo-embolic prophylaxis - atrial fibrillation - left atrial appendage occluder

• Literatur

• 1 Ansell JE, Bakhru SH, Laulicht BE et al. Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban. N Engl J Med 2014; 371: 2141-2142
• 2 Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747
• 3 Chao TF, Liu CJ, Wang KL et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS-VASc Score (beyond sex) receive oral anticoagulization?. J Am Coll Cardiol 2015; 65: 635-642
• 4 Deitelzweig SB, Jing Y, Swindle JP, Makenbaeva D. Reviewing a clinical decision aid for the selection of anticoagulation treatment in patients with nonvalvular atrial fibrillation: applications in a US managed care health plan database. Clin Ther 2014; 36: 1566-1573
• 5 Gloekler S, Shakir S, Doblies J et al. Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation. Clin Res Cardiol 2015; 104: 656-665
• 6 Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534-542
• 7 Kirchhof P, Ammentorp B, Darius H et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events – European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014; 16: 6-14
• 8 Kuramatsu JB, Gerner ST, Schellinger PD et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313: 824-836
• 9 Meier B, Blaauw Y, Khattab AA et al. EHRA / EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace 2014; 16: 1397-1416
• 10 Reddy VY, Sievert H, Halperin J et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 2014; 312: 1988-1998
• 11 Sardar P, Chatterjee S, Lavie CJ et al. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J Cardiol 2015; 179: 279-287
• 12 Thompson PL, Verheugt FW. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. Clin Ther 2014; 36: 1176-1181